Raltitrexed_112887-68-0_DataSheet_MedChemExpress

  • 格式:pdf
  • 大小:69.89 KB
  • 文档页数:1

Product Name:
Raltitrexed CAS No.:
112887-68-0Cat. No.:
HY-10821Product Data Sheet
MWt:
458.49Formula:
C21H22N4O6S Purity :>98%
Solubility:
DMSO 82 mg/mL; Water <1 mg/mL
y Mechanisms:
Biological Activity:
Raltitrexed(ZD1694)an inhibitor of thymidylate synthase is an antimetabolite drug used in cancer
Pathways:Others; Target:Others g ;g Raltitrexed(ZD1694), an inhibitor of thymidylate synthase, is an antimetabolite drug used in cancer
chemotherapy.
Target: Thymidylate Synthase Raltitrexed (ZD1694) is a novel quinazoline folate analog that selectively inhibits thymidylate
synthase. Intracellularly, raltitrexed is polyglutamated to its active form which can be retained in cells for prolonged periods. The clearance of raltitrexed ranged from 110 to 165 ml/min per m(2), and the steady-state volume of distribution exceeded 200 l/m(2). The CSF penetration of raltitrexed was limited (0.6 to 2.0%) and drug could only be detected in the CSF following a 10 mg/m(2 )dose [1].ZD1694 has a spectrum of activity that only partially overlaps with 5-fluorouracil (modulated with References:
[1]. Widemann, B.C., et al., The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model. Cancer
Chemother Pharmacol, 1999. 44(6): p. 439-43.p y y p y p (
leucovorin) against colon tumours in vitro. ZD1694 has antitumour activity in mice. ZD1694 entered clinical study and has completed Phase I an...
[2]. Jackman, A.L., et al., ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in
colorectal cancer. Eur J Cancer, 1995. 31A(7-8): p. 1277-82.Caution: Not fully tested. For research purposes only
Medchemexpress LLC
18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b
: w w w .m e d c h e m e x p r e s s .c o m。